Cargando…
Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is the most common acute leukemia that is becoming more prevalent particularly in the older (65 years of age or older) population. For decades, “7 + 3” remission induction therapy with cytarabine and an anthracycline, followed by consolidation therapy, has been the stand...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6591181/ https://www.ncbi.nlm.nih.gov/pubmed/31236772 http://dx.doi.org/10.1007/s11095-019-2654-z |
_version_ | 1783429674520543232 |
---|---|
author | Chen, Kent T. J. Gilabert-Oriol, Roger Bally, Marcel B. Leung, Ada W. Y. |
author_facet | Chen, Kent T. J. Gilabert-Oriol, Roger Bally, Marcel B. Leung, Ada W. Y. |
author_sort | Chen, Kent T. J. |
collection | PubMed |
description | Acute myeloid leukemia (AML) is the most common acute leukemia that is becoming more prevalent particularly in the older (65 years of age or older) population. For decades, “7 + 3” remission induction therapy with cytarabine and an anthracycline, followed by consolidation therapy, has been the standard of care treatment for AML. This stagnancy in AML treatment has resulted in less than ideal treatment outcomes for AML patients, especially for elderly patients and those with unfavourable profiles. Over the past two years, six new therapeutic agents have received regulatory approval, suggesting that a number of obstacles to treating AML have been addressed and the treatment landscape for AML is finally changing. This review outlines the challenges and obstacles in treating AML and highlights the advances in AML treatment made in recent years, including Vyxeos®, midostaurin, gemtuzumab ozogamicin, and venetoclax, with particular emphasis on combination treatment strategies. We also discuss the potential utility of new combination products such as one that we call “EnFlaM”, which comprises an encapsulated nanoformulation of flavopiridol and mitoxantrone. Finally, we provide a review on the immunotherapeutic landscape of AML, discussing yet another angle through which novel treatments can be designed to further improve treatment outcomes for AML patients. |
format | Online Article Text |
id | pubmed-6591181 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-65911812019-07-11 Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia Chen, Kent T. J. Gilabert-Oriol, Roger Bally, Marcel B. Leung, Ada W. Y. Pharm Res Expert Review Acute myeloid leukemia (AML) is the most common acute leukemia that is becoming more prevalent particularly in the older (65 years of age or older) population. For decades, “7 + 3” remission induction therapy with cytarabine and an anthracycline, followed by consolidation therapy, has been the standard of care treatment for AML. This stagnancy in AML treatment has resulted in less than ideal treatment outcomes for AML patients, especially for elderly patients and those with unfavourable profiles. Over the past two years, six new therapeutic agents have received regulatory approval, suggesting that a number of obstacles to treating AML have been addressed and the treatment landscape for AML is finally changing. This review outlines the challenges and obstacles in treating AML and highlights the advances in AML treatment made in recent years, including Vyxeos®, midostaurin, gemtuzumab ozogamicin, and venetoclax, with particular emphasis on combination treatment strategies. We also discuss the potential utility of new combination products such as one that we call “EnFlaM”, which comprises an encapsulated nanoformulation of flavopiridol and mitoxantrone. Finally, we provide a review on the immunotherapeutic landscape of AML, discussing yet another angle through which novel treatments can be designed to further improve treatment outcomes for AML patients. Springer US 2019-06-24 2019 /pmc/articles/PMC6591181/ /pubmed/31236772 http://dx.doi.org/10.1007/s11095-019-2654-z Text en © The Author(s) 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Expert Review Chen, Kent T. J. Gilabert-Oriol, Roger Bally, Marcel B. Leung, Ada W. Y. Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia |
title | Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia |
title_full | Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia |
title_fullStr | Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia |
title_full_unstemmed | Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia |
title_short | Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia |
title_sort | recent treatment advances and the role of nanotechnology, combination products, and immunotherapy in changing the therapeutic landscape of acute myeloid leukemia |
topic | Expert Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6591181/ https://www.ncbi.nlm.nih.gov/pubmed/31236772 http://dx.doi.org/10.1007/s11095-019-2654-z |
work_keys_str_mv | AT chenkenttj recenttreatmentadvancesandtheroleofnanotechnologycombinationproductsandimmunotherapyinchangingthetherapeuticlandscapeofacutemyeloidleukemia AT gilabertoriolroger recenttreatmentadvancesandtheroleofnanotechnologycombinationproductsandimmunotherapyinchangingthetherapeuticlandscapeofacutemyeloidleukemia AT ballymarcelb recenttreatmentadvancesandtheroleofnanotechnologycombinationproductsandimmunotherapyinchangingthetherapeuticlandscapeofacutemyeloidleukemia AT leungadawy recenttreatmentadvancesandtheroleofnanotechnologycombinationproductsandimmunotherapyinchangingthetherapeuticlandscapeofacutemyeloidleukemia |